Bayer HealthCare has submitted VEGF Trap-Eye (aflibercept solution for injection) for regulatory approval in Japan to treat patients with myopic choroidal neovascularization (myopic CNV), one of the most common causes of eye disease. In ...
Lumenis has obtained the US Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW) approvals for its Array LaserLink pattern scanning device for multi-spot laser photocoagulation for use during ...
Tags: Lumenis, Laser Treatment
Novartis has received an approval from the European Commission for its Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). Lucentis is a ...
The European Commission (EC) has approved Bayer HealthCare's EYLEA (aflibercept solution for injection) at a recommended dose of 2 mg for the treatment of wet age-related macular degeneration (wet AMD). Formulated as an iso-osmotic ...
Tags: European Commission, Bayer, Aflibercept Solution, EYLEA
Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin has signed a co-promotion agreement with Santen Pharmaceutical for Eylea (aflibercept) injection in Japan. Eylea is approved for sale in the US and Australia for the treatment of ...